nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—Dizziness—Vinblastine—hematologic cancer	0.00108	0.00131	CcSEcCtD
Mepenzolate—Insomnia—Alitretinoin—hematologic cancer	0.00108	0.00131	CcSEcCtD
Mepenzolate—Urticaria—Vinorelbine—hematologic cancer	0.00108	0.00131	CcSEcCtD
Mepenzolate—Constipation—Thalidomide—hematologic cancer	0.00107	0.0013	CcSEcCtD
Mepenzolate—Somnolence—Carmustine—hematologic cancer	0.00107	0.0013	CcSEcCtD
Mepenzolate—Asthenia—Hydroxyurea—hematologic cancer	0.00107	0.0013	CcSEcCtD
Mepenzolate—Feeling abnormal—Thiotepa—hematologic cancer	0.00107	0.0013	CcSEcCtD
Mepenzolate—Headache—Cladribine—hematologic cancer	0.00106	0.00129	CcSEcCtD
Mepenzolate—Vision blurred—Prednisolone—hematologic cancer	0.00106	0.00129	CcSEcCtD
Mepenzolate—Somnolence—Alitretinoin—hematologic cancer	0.00106	0.00129	CcSEcCtD
Mepenzolate—Nausea—Chlorambucil—hematologic cancer	0.00106	0.00128	CcSEcCtD
Mepenzolate—Somnolence—Ifosfamide—hematologic cancer	0.00105	0.00127	CcSEcCtD
Mepenzolate—Insomnia—Vincristine—hematologic cancer	0.00104	0.00126	CcSEcCtD
Mepenzolate—Vomiting—Vinblastine—hematologic cancer	0.00104	0.00126	CcSEcCtD
Mepenzolate—Nausea—Nilotinib—hematologic cancer	0.00103	0.00126	CcSEcCtD
Mepenzolate—Feeling abnormal—Thalidomide—hematologic cancer	0.00103	0.00125	CcSEcCtD
Mepenzolate—Urticaria—Thiotepa—hematologic cancer	0.00103	0.00125	CcSEcCtD
Mepenzolate—Constipation—Carmustine—hematologic cancer	0.00103	0.00125	CcSEcCtD
Mepenzolate—Nausea—Imatinib—hematologic cancer	0.00103	0.00125	CcSEcCtD
Mepenzolate—Hypersensitivity—Bortezomib—hematologic cancer	0.00102	0.00124	CcSEcCtD
Mepenzolate—Headache—Vinblastine—hematologic cancer	0.00102	0.00124	CcSEcCtD
Mepenzolate—Constipation—Alitretinoin—hematologic cancer	0.00102	0.00124	CcSEcCtD
Mepenzolate—Anaphylactic shock—Cisplatin—hematologic cancer	0.00101	0.00123	CcSEcCtD
Mepenzolate—Hypersensitivity—Bleomycin—hematologic cancer	0.00101	0.00123	CcSEcCtD
Mepenzolate—Insomnia—Irinotecan—hematologic cancer	0.00101	0.00123	CcSEcCtD
Mepenzolate—Nausea—Cladribine—hematologic cancer	0.00101	0.00123	CcSEcCtD
Mepenzolate—Constipation—Ifosfamide—hematologic cancer	0.00101	0.00122	CcSEcCtD
Mepenzolate—Hypersensitivity—Vinorelbine—hematologic cancer	0.000998	0.00121	CcSEcCtD
Mepenzolate—Dizziness—Lenalidomide—hematologic cancer	0.000997	0.00121	CcSEcCtD
Mepenzolate—Asthenia—Bortezomib—hematologic cancer	0.000995	0.00121	CcSEcCtD
Mepenzolate—Urticaria—Thalidomide—hematologic cancer	0.000994	0.00121	CcSEcCtD
Mepenzolate—Somnolence—Mitoxantrone—hematologic cancer	0.000993	0.00121	CcSEcCtD
Mepenzolate—Somnolence—Irinotecan—hematologic cancer	0.000993	0.00121	CcSEcCtD
Mepenzolate—Feeling abnormal—Carmustine—hematologic cancer	0.00099	0.0012	CcSEcCtD
Mepenzolate—Tachycardia—Cisplatin—hematologic cancer	0.00099	0.0012	CcSEcCtD
Mepenzolate—Asthenia—Bleomycin—hematologic cancer	0.000987	0.0012	CcSEcCtD
Mepenzolate—Vomiting—Melphalan—hematologic cancer	0.000986	0.0012	CcSEcCtD
Mepenzolate—Insomnia—Gemcitabine—hematologic cancer	0.000984	0.0012	CcSEcCtD
Mepenzolate—Dizziness—Hydroxyurea—hematologic cancer	0.000983	0.0012	CcSEcCtD
Mepenzolate—Feeling abnormal—Alitretinoin—hematologic cancer	0.000981	0.00119	CcSEcCtD
Mepenzolate—Constipation—Vincristine—hematologic cancer	0.000981	0.00119	CcSEcCtD
Mepenzolate—Asthenia—Vinorelbine—hematologic cancer	0.000972	0.00118	CcSEcCtD
Mepenzolate—Feeling abnormal—Ifosfamide—hematologic cancer	0.000969	0.00118	CcSEcCtD
Mepenzolate—Nausea—Vinblastine—hematologic cancer	0.000968	0.00118	CcSEcCtD
Mepenzolate—Somnolence—Gemcitabine—hematologic cancer	0.000967	0.00118	CcSEcCtD
Mepenzolate—Vomiting—Lenalidomide—hematologic cancer	0.000958	0.00117	CcSEcCtD
Mepenzolate—Constipation—Mitoxantrone—hematologic cancer	0.000955	0.00116	CcSEcCtD
Mepenzolate—Constipation—Irinotecan—hematologic cancer	0.000955	0.00116	CcSEcCtD
Mepenzolate—Hypersensitivity—Thiotepa—hematologic cancer	0.000953	0.00116	CcSEcCtD
Mepenzolate—Urticaria—Alitretinoin—hematologic cancer	0.000945	0.00115	CcSEcCtD
Mepenzolate—Vomiting—Hydroxyurea—hematologic cancer	0.000945	0.00115	CcSEcCtD
Mepenzolate—Headache—Lenalidomide—hematologic cancer	0.000944	0.00115	CcSEcCtD
Mepenzolate—Confusional state—Etoposide—hematologic cancer	0.000937	0.00114	CcSEcCtD
Mepenzolate—Urticaria—Ifosfamide—hematologic cancer	0.000934	0.00114	CcSEcCtD
Mepenzolate—Headache—Hydroxyurea—hematologic cancer	0.000931	0.00113	CcSEcCtD
Mepenzolate—Constipation—Gemcitabine—hematologic cancer	0.00093	0.00113	CcSEcCtD
Mepenzolate—Anaphylactic shock—Etoposide—hematologic cancer	0.000929	0.00113	CcSEcCtD
Mepenzolate—Asthenia—Thiotepa—hematologic cancer	0.000928	0.00113	CcSEcCtD
Mepenzolate—Abdominal distension—Epirubicin—hematologic cancer	0.000922	0.00112	CcSEcCtD
Mepenzolate—Hypersensitivity—Thalidomide—hematologic cancer	0.000922	0.00112	CcSEcCtD
Mepenzolate—Nausea—Melphalan—hematologic cancer	0.000921	0.00112	CcSEcCtD
Mepenzolate—Feeling abnormal—Irinotecan—hematologic cancer	0.00092	0.00112	CcSEcCtD
Mepenzolate—Feeling abnormal—Mitoxantrone—hematologic cancer	0.00092	0.00112	CcSEcCtD
Mepenzolate—Dizziness—Bortezomib—hematologic cancer	0.000917	0.00112	CcSEcCtD
Mepenzolate—Anaphylactic shock—Prednisolone—hematologic cancer	0.000916	0.00111	CcSEcCtD
Mepenzolate—Tachycardia—Etoposide—hematologic cancer	0.000907	0.0011	CcSEcCtD
Mepenzolate—Erectile dysfunction—Methotrexate—hematologic cancer	0.000901	0.0011	CcSEcCtD
Mepenzolate—Asthenia—Thalidomide—hematologic cancer	0.000897	0.00109	CcSEcCtD
Mepenzolate—Feeling abnormal—Gemcitabine—hematologic cancer	0.000897	0.00109	CcSEcCtD
Mepenzolate—Dizziness—Vinorelbine—hematologic cancer	0.000896	0.00109	CcSEcCtD
Mepenzolate—Nausea—Lenalidomide—hematologic cancer	0.000895	0.00109	CcSEcCtD
Mepenzolate—Tachycardia—Prednisolone—hematologic cancer	0.000894	0.00109	CcSEcCtD
Mepenzolate—Urticaria—Mitoxantrone—hematologic cancer	0.000887	0.00108	CcSEcCtD
Mepenzolate—Hypersensitivity—Carmustine—hematologic cancer	0.000885	0.00108	CcSEcCtD
Mepenzolate—Nausea—Hydroxyurea—hematologic cancer	0.000883	0.00107	CcSEcCtD
Mepenzolate—Vomiting—Bortezomib—hematologic cancer	0.000882	0.00107	CcSEcCtD
Mepenzolate—Hypersensitivity—Alitretinoin—hematologic cancer	0.000877	0.00107	CcSEcCtD
Mepenzolate—Vomiting—Bleomycin—hematologic cancer	0.000875	0.00106	CcSEcCtD
Mepenzolate—Drowsiness—Methotrexate—hematologic cancer	0.000872	0.00106	CcSEcCtD
Mepenzolate—Headache—Bortezomib—hematologic cancer	0.000869	0.00106	CcSEcCtD
Mepenzolate—Hypersensitivity—Ifosfamide—hematologic cancer	0.000867	0.00105	CcSEcCtD
Mepenzolate—Asthenia—Carmustine—hematologic cancer	0.000862	0.00105	CcSEcCtD
Mepenzolate—Vomiting—Vinorelbine—hematologic cancer	0.000861	0.00105	CcSEcCtD
Mepenzolate—Dry mouth—Triamcinolone—hematologic cancer	0.00086	0.00105	CcSEcCtD
Mepenzolate—Dizziness—Thiotepa—hematologic cancer	0.000855	0.00104	CcSEcCtD
Mepenzolate—Asthenia—Alitretinoin—hematologic cancer	0.000854	0.00104	CcSEcCtD
Mepenzolate—Abdominal distension—Doxorubicin—hematologic cancer	0.000853	0.00104	CcSEcCtD
Mepenzolate—Headache—Vinorelbine—hematologic cancer	0.000848	0.00103	CcSEcCtD
Mepenzolate—Hypersensitivity—Vincristine—hematologic cancer	0.000845	0.00103	CcSEcCtD
Mepenzolate—Asthenia—Ifosfamide—hematologic cancer	0.000844	0.00103	CcSEcCtD
Mepenzolate—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000843	0.00102	CcSEcCtD
Mepenzolate—Feeling abnormal—Cisplatin—hematologic cancer	0.000836	0.00102	CcSEcCtD
Mepenzolate—Insomnia—Prednisolone—hematologic cancer	0.000829	0.00101	CcSEcCtD
Mepenzolate—Dizziness—Thalidomide—hematologic cancer	0.000827	0.00101	CcSEcCtD
Mepenzolate—Somnolence—Etoposide—hematologic cancer	0.000826	0.001	CcSEcCtD
Mepenzolate—Nausea—Bortezomib—hematologic cancer	0.000824	0.001	CcSEcCtD
Mepenzolate—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000823	0.001	CcSEcCtD
Mepenzolate—Hypersensitivity—Irinotecan—hematologic cancer	0.000823	0.001	CcSEcCtD
Mepenzolate—Asthenia—Vincristine—hematologic cancer	0.000823	0.001	CcSEcCtD
Mepenzolate—Tachycardia—Triamcinolone—hematologic cancer	0.000822	0.001	CcSEcCtD
Mepenzolate—Vomiting—Thiotepa—hematologic cancer	0.000822	0.001	CcSEcCtD
Mepenzolate—Nausea—Bleomycin—hematologic cancer	0.000818	0.000994	CcSEcCtD
Mepenzolate—Drowsiness—Epirubicin—hematologic cancer	0.000816	0.000993	CcSEcCtD
Mepenzolate—Headache—Thiotepa—hematologic cancer	0.00081	0.000985	CcSEcCtD
Mepenzolate—Nausea—Vinorelbine—hematologic cancer	0.000804	0.000978	CcSEcCtD
Mepenzolate—Asthenia—Mitoxantrone—hematologic cancer	0.000801	0.000975	CcSEcCtD
Mepenzolate—Asthenia—Irinotecan—hematologic cancer	0.000801	0.000975	CcSEcCtD
Mepenzolate—Vomiting—Thalidomide—hematologic cancer	0.000795	0.000967	CcSEcCtD
Mepenzolate—Dizziness—Carmustine—hematologic cancer	0.000794	0.000966	CcSEcCtD
Mepenzolate—Constipation—Etoposide—hematologic cancer	0.000794	0.000966	CcSEcCtD
Mepenzolate—Dizziness—Alitretinoin—hematologic cancer	0.000787	0.000957	CcSEcCtD
Mepenzolate—Headache—Thalidomide—hematologic cancer	0.000784	0.000953	CcSEcCtD
Mepenzolate—Asthenia—Gemcitabine—hematologic cancer	0.000781	0.000949	CcSEcCtD
Mepenzolate—Dizziness—Ifosfamide—hematologic cancer	0.000778	0.000946	CcSEcCtD
Mepenzolate—Vision blurred—Prednisone—hematologic cancer	0.000769	0.000935	CcSEcCtD
Mepenzolate—Nausea—Thiotepa—hematologic cancer	0.000768	0.000934	CcSEcCtD
Mepenzolate—Feeling abnormal—Etoposide—hematologic cancer	0.000766	0.000931	CcSEcCtD
Mepenzolate—Anaphylactic shock—Betamethasone—hematologic cancer	0.000765	0.00093	CcSEcCtD
Mepenzolate—Anaphylactic shock—Dexamethasone—hematologic cancer	0.000765	0.00093	CcSEcCtD
Mepenzolate—Vomiting—Carmustine—hematologic cancer	0.000764	0.000929	CcSEcCtD
Mepenzolate—Insomnia—Triamcinolone—hematologic cancer	0.000762	0.000927	CcSEcCtD
Mepenzolate—Dizziness—Vincristine—hematologic cancer	0.000758	0.000922	CcSEcCtD
Mepenzolate—Vomiting—Alitretinoin—hematologic cancer	0.000757	0.00092	CcSEcCtD
Mepenzolate—Drowsiness—Doxorubicin—hematologic cancer	0.000755	0.000919	CcSEcCtD
Mepenzolate—Feeling abnormal—Prednisolone—hematologic cancer	0.000755	0.000918	CcSEcCtD
Mepenzolate—Headache—Carmustine—hematologic cancer	0.000753	0.000915	CcSEcCtD
Mepenzolate—Vomiting—Ifosfamide—hematologic cancer	0.000748	0.00091	CcSEcCtD
Mepenzolate—Hypersensitivity—Cisplatin—hematologic cancer	0.000747	0.000909	CcSEcCtD
Mepenzolate—Tachycardia—Dexamethasone—hematologic cancer	0.000746	0.000908	CcSEcCtD
Mepenzolate—Tachycardia—Betamethasone—hematologic cancer	0.000746	0.000908	CcSEcCtD
Mepenzolate—Headache—Alitretinoin—hematologic cancer	0.000746	0.000907	CcSEcCtD
Mepenzolate—Nausea—Thalidomide—hematologic cancer	0.000743	0.000904	CcSEcCtD
Mepenzolate—Dizziness—Irinotecan—hematologic cancer	0.000739	0.000898	CcSEcCtD
Mepenzolate—Urticaria—Etoposide—hematologic cancer	0.000738	0.000898	CcSEcCtD
Mepenzolate—Vomiting—Vincristine—hematologic cancer	0.000729	0.000887	CcSEcCtD
Mepenzolate—Urticaria—Prednisolone—hematologic cancer	0.000728	0.000885	CcSEcCtD
Mepenzolate—Asthenia—Cisplatin—hematologic cancer	0.000728	0.000885	CcSEcCtD
Mepenzolate—Headache—Vincristine—hematologic cancer	0.000718	0.000874	CcSEcCtD
Mepenzolate—Nausea—Carmustine—hematologic cancer	0.000714	0.000868	CcSEcCtD
Mepenzolate—Vomiting—Irinotecan—hematologic cancer	0.00071	0.000864	CcSEcCtD
Mepenzolate—Vomiting—Mitoxantrone—hematologic cancer	0.00071	0.000864	CcSEcCtD
Mepenzolate—Nausea—Alitretinoin—hematologic cancer	0.000707	0.00086	CcSEcCtD
Mepenzolate—Headache—Mitoxantrone—hematologic cancer	0.0007	0.000851	CcSEcCtD
Mepenzolate—Headache—Irinotecan—hematologic cancer	0.0007	0.000851	CcSEcCtD
Mepenzolate—Nausea—Ifosfamide—hematologic cancer	0.000699	0.00085	CcSEcCtD
Mepenzolate—Feeling abnormal—Triamcinolone—hematologic cancer	0.000694	0.000845	CcSEcCtD
Mepenzolate—Vomiting—Gemcitabine—hematologic cancer	0.000692	0.000841	CcSEcCtD
Mepenzolate—Insomnia—Betamethasone—hematologic cancer	0.000692	0.000841	CcSEcCtD
Mepenzolate—Insomnia—Dexamethasone—hematologic cancer	0.000692	0.000841	CcSEcCtD
Mepenzolate—Hypersensitivity—Etoposide—hematologic cancer	0.000684	0.000832	CcSEcCtD
Mepenzolate—Headache—Gemcitabine—hematologic cancer	0.000682	0.000829	CcSEcCtD
Mepenzolate—Nausea—Vincristine—hematologic cancer	0.000681	0.000829	CcSEcCtD
Mepenzolate—Hypersensitivity—Prednisolone—hematologic cancer	0.000675	0.000821	CcSEcCtD
Mepenzolate—Urticaria—Triamcinolone—hematologic cancer	0.000669	0.000814	CcSEcCtD
Mepenzolate—Asthenia—Etoposide—hematologic cancer	0.000667	0.000811	CcSEcCtD
Mepenzolate—Anaphylactic shock—Prednisone—hematologic cancer	0.000666	0.00081	CcSEcCtD
Mepenzolate—Nausea—Mitoxantrone—hematologic cancer	0.000663	0.000807	CcSEcCtD
Mepenzolate—Nausea—Irinotecan—hematologic cancer	0.000663	0.000807	CcSEcCtD
Mepenzolate—Tachycardia—Prednisone—hematologic cancer	0.00065	0.00079	CcSEcCtD
Mepenzolate—Nausea—Gemcitabine—hematologic cancer	0.000646	0.000786	CcSEcCtD
Mepenzolate—Vomiting—Cisplatin—hematologic cancer	0.000645	0.000784	CcSEcCtD
Mepenzolate—Vision blurred—Methotrexate—hematologic cancer	0.000643	0.000782	CcSEcCtD
Mepenzolate—Feeling abnormal—Dexamethasone—hematologic cancer	0.00063	0.000766	CcSEcCtD
Mepenzolate—Feeling abnormal—Betamethasone—hematologic cancer	0.00063	0.000766	CcSEcCtD
Mepenzolate—Tension—Epirubicin—hematologic cancer	0.000626	0.000762	CcSEcCtD
Mepenzolate—Hypersensitivity—Triamcinolone—hematologic cancer	0.000621	0.000755	CcSEcCtD
Mepenzolate—Nervousness—Epirubicin—hematologic cancer	0.00062	0.000754	CcSEcCtD
Mepenzolate—Dizziness—Etoposide—hematologic cancer	0.000614	0.000747	CcSEcCtD
Mepenzolate—Urticaria—Betamethasone—hematologic cancer	0.000607	0.000739	CcSEcCtD
Mepenzolate—Urticaria—Dexamethasone—hematologic cancer	0.000607	0.000739	CcSEcCtD
Mepenzolate—Dizziness—Prednisolone—hematologic cancer	0.000606	0.000737	CcSEcCtD
Mepenzolate—Asthenia—Triamcinolone—hematologic cancer	0.000605	0.000735	CcSEcCtD
Mepenzolate—Nausea—Cisplatin—hematologic cancer	0.000602	0.000733	CcSEcCtD
Mepenzolate—Insomnia—Prednisone—hematologic cancer	0.000602	0.000732	CcSEcCtD
Mepenzolate—Vision blurred—Epirubicin—hematologic cancer	0.000601	0.000731	CcSEcCtD
Mepenzolate—Vomiting—Etoposide—hematologic cancer	0.000591	0.000718	CcSEcCtD
Mepenzolate—Headache—Etoposide—hematologic cancer	0.000582	0.000708	CcSEcCtD
Mepenzolate—Tension—Doxorubicin—hematologic cancer	0.000579	0.000705	CcSEcCtD
Mepenzolate—Headache—Prednisolone—hematologic cancer	0.000574	0.000698	CcSEcCtD
Mepenzolate—Nervousness—Doxorubicin—hematologic cancer	0.000573	0.000697	CcSEcCtD
Mepenzolate—Constipation—Prednisone—hematologic cancer	0.000569	0.000693	CcSEcCtD
Mepenzolate—Palpitations—Epirubicin—hematologic cancer	0.000564	0.000686	CcSEcCtD
Mepenzolate—Confusional state—Methotrexate—hematologic cancer	0.000561	0.000682	CcSEcCtD
Mepenzolate—Dizziness—Triamcinolone—hematologic cancer	0.000557	0.000678	CcSEcCtD
Mepenzolate—Anaphylactic shock—Methotrexate—hematologic cancer	0.000556	0.000677	CcSEcCtD
Mepenzolate—Vision blurred—Doxorubicin—hematologic cancer	0.000556	0.000677	CcSEcCtD
Mepenzolate—Nausea—Etoposide—hematologic cancer	0.000552	0.000671	CcSEcCtD
Mepenzolate—Feeling abnormal—Prednisone—hematologic cancer	0.000549	0.000667	CcSEcCtD
Mepenzolate—Asthenia—Dexamethasone—hematologic cancer	0.000549	0.000667	CcSEcCtD
Mepenzolate—Asthenia—Betamethasone—hematologic cancer	0.000549	0.000667	CcSEcCtD
Mepenzolate—Nausea—Prednisolone—hematologic cancer	0.000544	0.000662	CcSEcCtD
Mepenzolate—Vomiting—Triamcinolone—hematologic cancer	0.000536	0.000652	CcSEcCtD
Mepenzolate—Dry mouth—Epirubicin—hematologic cancer	0.000531	0.000646	CcSEcCtD
Mepenzolate—Urticaria—Prednisone—hematologic cancer	0.000529	0.000643	CcSEcCtD
Mepenzolate—Headache—Triamcinolone—hematologic cancer	0.000528	0.000642	CcSEcCtD
Mepenzolate—Confusional state—Epirubicin—hematologic cancer	0.000525	0.000639	CcSEcCtD
Mepenzolate—Palpitations—Doxorubicin—hematologic cancer	0.000522	0.000635	CcSEcCtD
Mepenzolate—Anaphylactic shock—Epirubicin—hematologic cancer	0.000521	0.000633	CcSEcCtD
Mepenzolate—Tachycardia—Epirubicin—hematologic cancer	0.000508	0.000618	CcSEcCtD
Mepenzolate—Dizziness—Betamethasone—hematologic cancer	0.000506	0.000615	CcSEcCtD
Mepenzolate—Dizziness—Dexamethasone—hematologic cancer	0.000506	0.000615	CcSEcCtD
Mepenzolate—Insomnia—Methotrexate—hematologic cancer	0.000503	0.000612	CcSEcCtD
Mepenzolate—Nausea—Triamcinolone—hematologic cancer	0.000501	0.000609	CcSEcCtD
Mepenzolate—Somnolence—Methotrexate—hematologic cancer	0.000495	0.000602	CcSEcCtD
Mepenzolate—Dry mouth—Doxorubicin—hematologic cancer	0.000492	0.000598	CcSEcCtD
Mepenzolate—Hypersensitivity—Prednisone—hematologic cancer	0.000491	0.000597	CcSEcCtD
Mepenzolate—Vomiting—Betamethasone—hematologic cancer	0.000486	0.000591	CcSEcCtD
Mepenzolate—Vomiting—Dexamethasone—hematologic cancer	0.000486	0.000591	CcSEcCtD
Mepenzolate—Confusional state—Doxorubicin—hematologic cancer	0.000486	0.000591	CcSEcCtD
Mepenzolate—Anaphylactic shock—Doxorubicin—hematologic cancer	0.000482	0.000586	CcSEcCtD
Mepenzolate—Headache—Betamethasone—hematologic cancer	0.000479	0.000583	CcSEcCtD
Mepenzolate—Headache—Dexamethasone—hematologic cancer	0.000479	0.000583	CcSEcCtD
Mepenzolate—Asthenia—Prednisone—hematologic cancer	0.000478	0.000581	CcSEcCtD
Mepenzolate—Insomnia—Epirubicin—hematologic cancer	0.000471	0.000573	CcSEcCtD
Mepenzolate—Tachycardia—Doxorubicin—hematologic cancer	0.00047	0.000572	CcSEcCtD
Mepenzolate—Somnolence—Epirubicin—hematologic cancer	0.000463	0.000563	CcSEcCtD
Mepenzolate—Feeling abnormal—Methotrexate—hematologic cancer	0.000459	0.000558	CcSEcCtD
Mepenzolate—Nausea—Dexamethasone—hematologic cancer	0.000454	0.000552	CcSEcCtD
Mepenzolate—Nausea—Betamethasone—hematologic cancer	0.000454	0.000552	CcSEcCtD
Mepenzolate—Constipation—Epirubicin—hematologic cancer	0.000445	0.000542	CcSEcCtD
Mepenzolate—Urticaria—Methotrexate—hematologic cancer	0.000442	0.000538	CcSEcCtD
Mepenzolate—Dizziness—Prednisone—hematologic cancer	0.00044	0.000536	CcSEcCtD
Mepenzolate—Insomnia—Doxorubicin—hematologic cancer	0.000436	0.00053	CcSEcCtD
Mepenzolate—Feeling abnormal—Epirubicin—hematologic cancer	0.000429	0.000522	CcSEcCtD
Mepenzolate—Somnolence—Doxorubicin—hematologic cancer	0.000428	0.000521	CcSEcCtD
Mepenzolate—Vomiting—Prednisone—hematologic cancer	0.000423	0.000515	CcSEcCtD
Mepenzolate—Headache—Prednisone—hematologic cancer	0.000417	0.000507	CcSEcCtD
Mepenzolate—Urticaria—Epirubicin—hematologic cancer	0.000414	0.000503	CcSEcCtD
Mepenzolate—Constipation—Doxorubicin—hematologic cancer	0.000412	0.000501	CcSEcCtD
Mepenzolate—Hypersensitivity—Methotrexate—hematologic cancer	0.00041	0.000499	CcSEcCtD
Mepenzolate—Asthenia—Methotrexate—hematologic cancer	0.000399	0.000486	CcSEcCtD
Mepenzolate—Feeling abnormal—Doxorubicin—hematologic cancer	0.000397	0.000483	CcSEcCtD
Mepenzolate—Nausea—Prednisone—hematologic cancer	0.000395	0.000481	CcSEcCtD
Mepenzolate—Hypersensitivity—Epirubicin—hematologic cancer	0.000384	0.000467	CcSEcCtD
Mepenzolate—Urticaria—Doxorubicin—hematologic cancer	0.000383	0.000466	CcSEcCtD
Mepenzolate—Asthenia—Epirubicin—hematologic cancer	0.000374	0.000454	CcSEcCtD
Mepenzolate—Dizziness—Methotrexate—hematologic cancer	0.000368	0.000448	CcSEcCtD
Mepenzolate—Hypersensitivity—Doxorubicin—hematologic cancer	0.000355	0.000432	CcSEcCtD
Mepenzolate—Vomiting—Methotrexate—hematologic cancer	0.000354	0.00043	CcSEcCtD
Mepenzolate—Headache—Methotrexate—hematologic cancer	0.000349	0.000424	CcSEcCtD
Mepenzolate—Asthenia—Doxorubicin—hematologic cancer	0.000346	0.00042	CcSEcCtD
Mepenzolate—Dizziness—Epirubicin—hematologic cancer	0.000344	0.000419	CcSEcCtD
Mepenzolate—Vomiting—Epirubicin—hematologic cancer	0.000331	0.000403	CcSEcCtD
Mepenzolate—Nausea—Methotrexate—hematologic cancer	0.000331	0.000402	CcSEcCtD
Mepenzolate—Headache—Epirubicin—hematologic cancer	0.000326	0.000397	CcSEcCtD
Mepenzolate—Dizziness—Doxorubicin—hematologic cancer	0.000319	0.000388	CcSEcCtD
Mepenzolate—Nausea—Epirubicin—hematologic cancer	0.000309	0.000376	CcSEcCtD
Mepenzolate—Vomiting—Doxorubicin—hematologic cancer	0.000306	0.000373	CcSEcCtD
Mepenzolate—Headache—Doxorubicin—hematologic cancer	0.000302	0.000367	CcSEcCtD
Mepenzolate—Nausea—Doxorubicin—hematologic cancer	0.000286	0.000348	CcSEcCtD
Mepenzolate—CHRM3—Signaling Pathways—PDGFA—hematologic cancer	4.32e-05	0.000243	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—MAP2K1—hematologic cancer	4.31e-05	0.000243	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GRB2—hematologic cancer	4.29e-05	0.000241	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CD—hematologic cancer	4.29e-05	0.000241	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PDGFA—hematologic cancer	4.28e-05	0.000241	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KITLG—hematologic cancer	4.27e-05	0.00024	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KITLG—hematologic cancer	4.26e-05	0.00024	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KITLG—hematologic cancer	4.22e-05	0.000237	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—STAT5A—hematologic cancer	4.18e-05	0.000235	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	4.17e-05	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—STAT5A—hematologic cancer	4.16e-05	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CB—hematologic cancer	4.15e-05	0.000234	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN2B—hematologic cancer	4.14e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—MTHFR—hematologic cancer	4.14e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN2B—hematologic cancer	4.13e-05	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STAT5A—hematologic cancer	4.12e-05	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CB—hematologic cancer	4.11e-05	0.000231	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3R1—hematologic cancer	4.1e-05	0.00023	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN2B—hematologic cancer	4.09e-05	0.00023	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3R1—hematologic cancer	4.09e-05	0.00023	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3R1—hematologic cancer	4.05e-05	0.000228	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CD86—hematologic cancer	4.01e-05	0.000225	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CD86—hematologic cancer	3.99e-05	0.000225	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—JAK2—hematologic cancer	3.98e-05	0.000224	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—JAK2—hematologic cancer	3.97e-05	0.000223	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CD86—hematologic cancer	3.95e-05	0.000222	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HES1—hematologic cancer	3.95e-05	0.000222	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HES1—hematologic cancer	3.94e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—JAK2—hematologic cancer	3.93e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NCOR1—hematologic cancer	3.93e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NCOR1—hematologic cancer	3.92e-05	0.00022	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HES1—hematologic cancer	3.9e-05	0.000219	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CSF2—hematologic cancer	3.88e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGF1—hematologic cancer	3.88e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NCOR1—hematologic cancer	3.88e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CSF2—hematologic cancer	3.87e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGF1—hematologic cancer	3.87e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CSF2—hematologic cancer	3.83e-05	0.000216	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGF1—hematologic cancer	3.83e-05	0.000216	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	3.83e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	3.83e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	3.82e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FOXO1—hematologic cancer	3.82e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—IL2—hematologic cancer	3.81e-05	0.000214	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PDGFRB—hematologic cancer	3.81e-05	0.000214	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	3.78e-05	0.000213	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FOXO1—hematologic cancer	3.78e-05	0.000213	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—IL2—hematologic cancer	3.78e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PDGFRB—hematologic cancer	3.77e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CB—hematologic cancer	3.77e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	3.76e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PDGFRA—hematologic cancer	3.75e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—JAK1—hematologic cancer	3.75e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	3.75e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	3.74e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—JAK1—hematologic cancer	3.74e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CB—hematologic cancer	3.74e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PDGFRA—hematologic cancer	3.71e-05	0.000209	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PRKCG—hematologic cancer	3.7e-05	0.000208	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—JAK1—hematologic cancer	3.7e-05	0.000208	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	3.5e-05	0.000197	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	3.49e-05	0.000196	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CG—hematologic cancer	3.48e-05	0.000196	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL2—hematologic cancer	3.47e-05	0.000195	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL2—hematologic cancer	3.46e-05	0.000195	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TERT—hematologic cancer	3.46e-05	0.000195	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	3.46e-05	0.000194	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TERT—hematologic cancer	3.45e-05	0.000194	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL2—hematologic cancer	3.43e-05	0.000193	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TERT—hematologic cancer	3.42e-05	0.000192	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	3.38e-05	0.00019	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	3.37e-05	0.000189	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	3.34e-05	0.000188	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TSC2—hematologic cancer	3.3e-05	0.000186	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TSC2—hematologic cancer	3.29e-05	0.000185	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TSC2—hematologic cancer	3.26e-05	0.000183	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CREBBP—hematologic cancer	3.22e-05	0.000181	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	3.18e-05	0.000179	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	3.17e-05	0.000178	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	3.15e-05	0.000177	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	3.14e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	3.14e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	3.11e-05	0.000175	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ESR1—hematologic cancer	3.09e-05	0.000174	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ESR1—hematologic cancer	3.08e-05	0.000173	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CD—hematologic cancer	3.06e-05	0.000172	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FN1—hematologic cancer	3.05e-05	0.000171	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ESR1—hematologic cancer	3.05e-05	0.000171	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FN1—hematologic cancer	3.04e-05	0.000171	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ALB—hematologic cancer	3.02e-05	0.00017	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	3.01e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—BAD—hematologic cancer	3.01e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FN1—hematologic cancer	3.01e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—BAD—hematologic cancer	3e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	3e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	2.98e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	2.97e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—BAD—hematologic cancer	2.97e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	2.97e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	2.94e-05	0.000166	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CD80—hematologic cancer	2.92e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	2.92e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KIT—hematologic cancer	2.92e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	2.92e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CD80—hematologic cancer	2.91e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KIT—hematologic cancer	2.91e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	2.91e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	2.91e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3R1—hematologic cancer	2.89e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CD80—hematologic cancer	2.88e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	2.88e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KIT—hematologic cancer	2.88e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	2.88e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	2.87e-05	0.000161	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	2.86e-05	0.000161	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	2.83e-05	0.000159	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	2.79e-05	0.000157	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	2.78e-05	0.000157	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CREB1—hematologic cancer	2.78e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CREB1—hematologic cancer	2.77e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	2.76e-05	0.000155	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—BRAF—hematologic cancer	2.74e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CREB1—hematologic cancer	2.74e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—BRAF—hematologic cancer	2.73e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCL2—hematologic cancer	2.72e-05	0.000153	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL6R—hematologic cancer	2.71e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCL2—hematologic cancer	2.71e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—BRAF—hematologic cancer	2.71e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	2.7e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL6R—hematologic cancer	2.7e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	2.7e-05	0.000152	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCL2—hematologic cancer	2.68e-05	0.000151	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL6R—hematologic cancer	2.67e-05	0.00015	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	2.67e-05	0.00015	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CB—hematologic cancer	2.66e-05	0.00015	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.58e-05	0.000145	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	2.57e-05	0.000145	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.56e-05	0.000144	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	2.56e-05	0.000144	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	2.55e-05	0.000143	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.54e-05	0.000143	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	2.53e-05	0.000142	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	2.53e-05	0.000142	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	2.51e-05	0.000141	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.51e-05	0.000141	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	2.5e-05	0.000141	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	2.48e-05	0.000139	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGF2—hematologic cancer	2.46e-05	0.000138	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGF2—hematologic cancer	2.45e-05	0.000138	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGF2—hematologic cancer	2.42e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.42e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	2.41e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	2.39e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—JAK2—hematologic cancer	2.35e-05	0.000132	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—JAK2—hematologic cancer	2.35e-05	0.000132	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—JAK2—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.31e-05	0.00013	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTEN—hematologic cancer	2.3e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	2.3e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MDM2—hematologic cancer	2.3e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MDM2—hematologic cancer	2.29e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	2.28e-05	0.000128	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MDM2—hematologic cancer	2.27e-05	0.000128	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MTOR—hematologic cancer	2.24e-05	0.000126	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.24e-05	0.000126	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	2.23e-05	0.000125	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MTOR—hematologic cancer	2.23e-05	0.000125	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	2.21e-05	0.000124	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MTOR—hematologic cancer	2.21e-05	0.000124	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—EP300—hematologic cancer	2.2e-05	0.000123	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	2.13e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	2.13e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	2.11e-05	0.000118	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.1e-05	0.000118	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	2.09e-05	0.000118	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.07e-05	0.000117	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	2.07e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	2.07e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CASP3—hematologic cancer	2.06e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL2—hematologic cancer	2.05e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CASP3—hematologic cancer	2.05e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	2.05e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL2—hematologic cancer	2.05e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL6—hematologic cancer	2.04e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL6—hematologic cancer	2.04e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CASP3—hematologic cancer	2.03e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL2—hematologic cancer	2.03e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL6—hematologic cancer	2.02e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCND1—hematologic cancer	2e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—JUN—hematologic cancer	2e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCND1—hematologic cancer	1.99e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—JUN—hematologic cancer	1.99e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCND1—hematologic cancer	1.98e-05	0.000111	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—JUN—hematologic cancer	1.97e-05	0.000111	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.94e-05	0.000109	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PTEN—hematologic cancer	1.93e-05	0.000109	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	1.93e-05	0.000109	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PTEN—hematologic cancer	1.93e-05	0.000108	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	1.91e-05	0.000107	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PTEN—hematologic cancer	1.91e-05	0.000107	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	1.89e-05	0.000106	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	1.87e-05	0.000105	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	1.86e-05	0.000105	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.84e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EP300—hematologic cancer	1.84e-05	0.000103	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EP300—hematologic cancer	1.82e-05	0.000102	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.79e-05	0.000101	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.79e-05	0.0001	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.77e-05	9.94e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.74e-05	9.81e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	1.74e-05	9.78e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.73e-05	9.71e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.72e-05	9.69e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.72e-05	9.68e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—STAT3—hematologic cancer	1.72e-05	9.68e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NRAS—hematologic cancer	1.72e-05	9.66e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.71e-05	9.59e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.7e-05	9.56e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.65e-05	9.28e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	1.65e-05	9.25e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.63e-05	9.16e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.62e-05	9.13e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.61e-05	9.03e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.6e-05	9e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.6e-05	9e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.6e-05	8.98e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.58e-05	8.91e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.58e-05	8.89e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.48e-05	8.34e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.48e-05	8.31e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.46e-05	8.23e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.36e-05	7.66e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	1.36e-05	7.64e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	1.35e-05	7.56e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—AKT1—hematologic cancer	1.33e-05	7.46e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.32e-05	7.41e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TP53—hematologic cancer	1.31e-05	7.39e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TP53—hematologic cancer	1.3e-05	7.32e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.26e-05	7.09e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HRAS—hematologic cancer	1.26e-05	7.07e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HRAS—hematologic cancer	1.24e-05	7e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.21e-05	6.78e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.2e-05	6.76e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.19e-05	6.7e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.11e-05	6.26e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.11e-05	6.24e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.1e-05	6.18e-05	CbGpPWpGaD
